Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 1
2011 2
2012 2
2014 5
2015 6
2016 4
2017 2
2018 4
2019 5
2020 4
2021 5
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulié M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Among authors: guillot a. J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254888 Clinical Trial.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Among authors: guillot a. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
General management of nonagenarian patients: a review of the literature.
Rivoirard R, Chargari C, Trone JC, Falk AT, Guy JB, Eddekaoui H, Lahmar R, Pacaut C, Mery B, Assouline A, Auberdiac P, Moriceau G, Gonthier R, Guillot A, Merrouche Y, Magné N. Rivoirard R, et al. Among authors: guillot a. Swiss Med Wkly. 2014 Dec 23;144:w14059. doi: 10.4414/smw.2014.14059. eCollection 2014. Swiss Med Wkly. 2014. PMID: 25536522 Free article. Review.
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S, Harter V, Krucker C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Fontugne J, Allory Y, Pfister C; VESPER Trial Investigators. Culine S, et al. Among authors: guillot a. Cancers (Basel). 2023 Mar 13;15(6):1742. doi: 10.3390/cancers15061742. Cancers (Basel). 2023. PMID: 36980628 Free PMC article.
Bifidobacterium species bacteremia: risk factors in adults and infants.
Weber E, Reynaud Q, Suy F, Gagneux-Brunon A, Carricajo A, Guillot A, Botelho-Nevers E. Weber E, et al. Among authors: guillot a. Clin Infect Dis. 2015 Aug 1;61(3):482-4. doi: 10.1093/cid/civ347. Epub 2015 Apr 28. Clin Infect Dis. 2015. PMID: 25921690 No abstract available.
40 results